NASDAQ$CRDF
Cardiff Oncology Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported third quarter 2022 results and provided business updates.
Cardiff Oncology announced Phase 1b/2 data demonstrating onvansertib's ability to generate durable responses in KRAS-mutated mCRC patients. The company plans to activate ONSEMBLE, a randomized Phase 2 trial in Q4 2022. Cardiff Oncology had approximately $114 million in cash, cash equivalents, and short-term investments as of September 30, 2022, providing projected runway into 2025.
- Data from Phase 1b/2 trial in KRAS-mutated metastatic colorectal cancer (mCRC) show durable responses to treatment.
- Data support initiation of ONSEMBLE, a randomized Phase 2 trial in KRAS/NRAS-mutated mCRC.
- ONSEMBLE trial on track for activation in Q4 2022.
- Cash, cash equivalents, and short-term investments of approximately $114 million as of September 30, 2022, provide projected runway into 2025.
Headline financials
Revenue & EPS history
Cardiff Oncology · Revenue · Quarterly
$93K
Revenue by segment
Cardiff Oncology · $41K total across 1 segment · Q1 2026
- Royalties$41K—100.0%
Forward guidance
The Company believes its current cash resources are sufficient to fund its operations into 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
+2.2%
Avg return
Earnings day
+1.9%
Avg return
5 days after
+2.8%
Avg return
30 days after
43%
28 / 65 earnings
Positive
+118.2%
Q4 2010
Best reaction
-21.2%
Q4 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.8% | +3.6% | -8.3% | |
| Q4 2025 | +12.9% | +14.1% | -8.8% | |
| Q3 2025 | -3.1% | -0.4% | -6.2% | |
| Q2 2025 | -1.3% | -24.2% | -36.6% | |
| Q1 2025 | +4.0% | +2.5% | +37.4% | |
| Q4 2024 | +4.4% | +5.2% | -19.0% | |
| Q3 2024 | -19.2% | -17.6% | -39.4% | |
| Q2 2024 | +11.2% | +5.1% | -1.4% | |
| Q1 2024 | -16.8% | -21.7% | -24.8% | |
| Q4 2023 | +59.9% | +100.5% | +193.4% | |
| Q3 2023 | +5.7% | +3.8% | +20.0% | |
| Q2 2023 | -5.0% | -8.3% | -15.6% | |
| Q1 2023 | +1.1% | -4.8% | -12.4% | |
| Q4 2022 | +2.3% | +7.6% | -4.1% | |
| Q3 2022 | -4.7% | -10.7% | +5.4% | |
| Q2 2022 | +15.0% | +30.0% | +27.7% | |
| Q1 2022 | -7.7% | -11.9% | -0.7% | |
| Q4 2021 | +7.1% | +0.4% | -5.6% | |
| Q3 2021 | -5.1% | -3.6% | -14.1% | |
| Q2 2021 | +15.0% | +19.4% | +51.3% | |
| Q1 2021 | -5.5% | -13.1% | -24.5% | |
| Q4 2020 | +0.6% | +8.0% | -3.1% | |
| Q3 2020 | +10.6% | +5.8% | +26.6% | |
| Q2 2020 | -14.6% | -10.2% | -3.4% | |
| Q1 2020 | +0.8% | +6.7% | +167.5% | |
| Q4 2019 | -2.8% | +12.8% | -24.1% | |
| Q3 2019 | +1.8% | +2.4% | -20.8% | |
| Q2 2019 | -4.1% | -10.0% | +10.6% | |
| Q1 2019 | -8.1% | -11.2% | -11.2% | |
| Q4 2018 | +25.2% | +47.0% | +18.2% | |
| Q3 2018 | +6.7% | +4.0% | -6.7% | |
| Q2 2018 | -1.2% | -1.2% | +0.0% | |
| Q1 2018 | +0.0% | -3.6% | -47.3% | |
| Q4 2017 | -6.2% | -3.1% | +6.2% | |
| Q3 2017 | -1.5% | -4.4% | -26.5% | |
| Q2 2017 | -7.1% | +1.2% | -13.1% | |
| Q1 2017 | -5.0% | -1.2% | +1.3% | |
| Q4 2016 | -21.2% | -28.5% | -37.0% | |
| Q3 2016 | -5.6% | -15.5% | -29.6% | |
| Q2 2016 | -6.6% | -0.4% | -11.0% | |
| Q1 2016 | -3.7% | — | — | |
| Q4 2015 | -18.7% | — | — | |
| Q3 2015 | +11.7% | — | — | |
| Q2 2015 | -15.0% | — | — | |
| Q1 2015 | +9.6% | — | — | |
| Q4 2014 | +0.3% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | +1.6% | — | — | |
| Q1 2014 | -2.3% | — | — | |
| Q4 2013 | +7.9% | — | — | |
| Q3 2013 | +12.2% | — | — | |
| Q2 2013 | -1.7% | — | — | |
| Q4 2012 | -2.4% | — | — | |
| Q1 2013 | -2.4% | — | — | |
| Q3 2012 | +2.3% | — | — | |
| Q2 2012 | -6.5% | — | — | |
| Q1 2012 | +8.8% | — | — | |
| Q4 2011 | -3.9% | — | — | |
| Q3 2011 | -17.1% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q4 2010 | +118.2% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +13.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro